BioLineRx (BLRX +2.3%) says Phase II/III results on BL-1020, an antipsychotic for the treatment of schizophrenia, are expected during the week of March 18. The interim analysis, which measures the effect of the drug on cognitive function, will be performed on data of approximately 235 randomized patients from 27 sites in Romania and India.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs